# Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

> **NCT01388621** · PHASE2 · UNKNOWN · sponsor: **WiSP Wissenschaftlicher Service Pharma GmbH** · enrollment: 140 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** pegylated liposomal doxorubicin (PLD)
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01388621
- **Lead sponsor:** WiSP Wissenschaftlicher Service Pharma GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2014-07
- **Final completion:** 2015-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2013-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388621, "Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01388621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*